Patents Assigned to Protera S.R.L.
  • Prodrugs activated by RNA-dependent DNA-polymerases
    Patent number: 8110676
    Abstract: The invention provides prodrugs activated by RNA-dependent DNA-polymerases, and methods for treating hematological tumors, blood, and blood derivatives from patients affected by retroviral infections by administering the prodrugs. The invention also provides methods for the preparation of pharmaceutical compositions containing the prodrugs.
    Type: Grant
    Filed: August 2, 2005
    Date of Patent: February 7, 2012
    Assignee: Protera S.R.L.
    Inventors: Ivano Bertini, Claudio Luchinat, Alessandro Quattrone, Massimo Calamante, Alessandro Mordini
  • Derivatives of arylsulfonamido-substituted hydroxamic acid as matrix metalloproteinases inhibitors
    Patent number: 7772430
    Abstract: Described herein are derivatives of arylsulfonamido-substituted hydroxamic acid of formula (I) having good solubility in water and inhibitory activity of matrix metalloproteinases, useful for the preparation of pharmaceutical compositions for the treatment of diseases associated to a pathologic activity and/or an over-expression of metalloproteinases, and of cosmetic preparations having anti-ageing properties in particular for hair and skin.
    Type: Grant
    Filed: July 29, 2005
    Date of Patent: August 10, 2010
    Assignee: Protera S.R.L.
    Inventors: Ivano Bertini, Marco Fragai, Mauro Lo Conte, Claudio Luchinat, Cristina Nativi, Chiara Venturi
  • Use of Matrix Metalloproteinases, Mutated and Not Mutated, for the Preparation of Pharmaceutical Compositions, and Mutated Metalloproteinases with Increased Stability
    Publication number: 20100047894
    Abstract: The use of matrix metalloproteinases, mutated and not mutated, for the preparation of pharmaceutical compositions useful in the treatment of pathologies associated with an accumulation of matrix bio-polymers and/or an excess of TIMPs (Tissue Inhihitors MetalloProteinases) is described; mutated matrix metalloproteinases, in which at least an aminoacid residue in a definite position in the protein, has been mutated into a hydrophilic and/or charged aminoacidic residue, obtaining an increased stability toward autoproteolysis are also described.
    Type: Application
    Filed: August 10, 2006
    Publication date: February 25, 2010
    Applicant: Protera S.R.L.
    Inventors: Ivano Bertini, Claudio Luchinat, Lucia Banci, Rebecca Del Conte, Marco Fragai
  • Prodrugs Activated by Rna-Dependent Dna-Polymerases
    Publication number: 20080300215
    Abstract: Herein described are prodrugs activated by RNA-dependent DNA-polymerases, such as telomerase and retroviral reverse transcriptases, their use for the treatment of haematological tumours and of blood and blood derivatives from patients affected by retroviral infections, and their use for the preparation of pharmaceutical compositions, to be used for the treatment of solid tumours, of precancerous states and of diseases caused by infection with retroviruses.
    Type: Application
    Filed: August 2, 2005
    Publication date: December 4, 2008
    Applicant: PROTERA S.R.L.
    Inventors: Ivano Bertini, Claudio Luchinat, Alessandro Quattrone, Massimo Calamante, Alessandro Mordini